Eric J. Sherman, MD, Discusses the Use of Adjuvant Capecitabine in Nasopharynx Cancer


Eric J. Sherman, MD, of Memorial Sloan Kettering Cancer Center highlights research on adjuvant capecitabine in nasopharynx cancer.

At the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, CancerNetwork® sat down with Eric J. Sherman, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, to discuss 2 phase 3 studies featuring the use of adjuvant capecitabine following cisplatin and radiation therapy in patients with advanced nasopharynx cancer (NCT02958111; NCT02143388).

In both studies, capecitabine yielded a survival benefit in patients and could possibly represent a new standard of care in this population. However, several questions still need to be answered, including as to whether adjuvant cisplatin plus 5-fluorouracil (5-FU) may be a better option and if induction chemotherapy is needed.


Two studies looked at the question of using capecitabine as adjuvant therapy for nasopharynx cancer, both looking at advanced nasopharynx cancer after cisplatin and radiation. One allowed neoadjuvant therapy, and the other did not. The one thing you saw pretty clearly is that adjuvant capecitabine led to a survival benefit—definitely a progression-free survival benefit, but it looks like an overall survival benefit, [too]. That’s really important. There’s a really big push away from adjuvant chemotherapy. This is showing that using a drug that can be given as a pill, not even [intravenous] treatment, and at reasonable doses, leads to a benefit independent of whether [the patient had] adjuvant therapy or not. These were not the high doses of capecitabine: One [study used] 1000 mg/m2 for 2 weeks on/1 week off, and the other study used just 650 mg/m2 twice a day, continued for a full year…This is something that may be a real [practice] changer in how we treat.

The question is, do we go this capecitabine route? Do we continue to do cisplatin and 5-FU as an adjuvant therapy? Do we need induction chemotherapy plus adjuvant therapy? There are still some questions that exist, but this may easily become a new standard of care for nasopharynx cancer, especially since capecitabine is an easy drug for us to get in the United States. It will be interesting to see how the FDA views both of those clinical studies.

Those are the 2 real potential game changers in the sense that they may change [our] practice [for] head and neck cancer, even in the next month or 2. [However], both of these approaches [have] some controversy and it is going to be something that everyone is going to have to discuss a lot further to figure out what their true role is in standard of therapy.


  1. Ma J, Chen YP, Sun Y, et al. Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicenter, randomized controlled trial. J Clin Oncol. 2021;39(suppl 15):6003. doi:10.1200/JCO.2021.39.15_suppl.6003
  2. Miao J, Wang L, Tan SH, et al. Adjuvant capecitabine in locoregionally advanced nasopharyngeal carcinoma: a multicenter randomized controlled phase III trial. J Clin Oncol. 2021;39(suppl 15):6005 doi:10.1200/JCO.2021.39.15_suppl.6005
Related Videos
Common adverse effects following treatment with lenvatinib plus pembrolizumab in the phase 3 CLEAR study include diarrhea, hypertension, and fatigue, according to Thomas E. Hutson, DO, PharmD, FACP.
Lenvatinib in combination with pembrolizumab appears to raise no new safety signals in patients with advanced clear cell renal cell carcinoma after 4 years of follow-up in the phase 3 CLEAR study.
According to Thomas E. Hutson, DO, PharmD, FACP, 4-year follow-up data from the phase 3 CLEAR study confirm the maintained benefits of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Rana R. McKay, MD discusses presentations of interest that were presented at the 2023 Kidney Cancer Research Summit, including a discussion on how PET imaging may identify which patients with renal cell carcinoma may respond to immunotherapy.
A better understanding of tumor biology may be necessary for identifying novel non-immunotherapy–based therapeutic strategies for patients with renal cell carcinoma, according to Rana R. McKay, MD.
Probiotics and other agents targeting fatty acid oxidation are also under evaluation as treatment options for patients with renal cell carcinoma, according to Rana R. McKay, MD.
Other angiogenic agents are also under investigation in renal cell carcinoma, according to Rana McKay, MD, who indicates it will be interesting to see how they compare with belzutifan.
Trastuzumab deruxtecan appears to elicit ‘impressive’ responses among patients with HER2-positive gynecologic cancers regardless of immunohistochemistry in the phase 2 DESTINY-PanTumor02 trial.
Ritu Salani, MD, highlights the possible benefit of a novel targeted therapy and autologous tumor vaccine in patients with platinum-resistant ovarian cancer, and in the maintenance setting after treatment for platinum-sensitive disease.